Enteris BioPharma's Licensing Partner, Cara Therapeutics, Announces Top Line Data from Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA(TM) for the Treatment of Pruritus in Patients with Advanced Chronic Kidney Disease (CKD)

Stock Information for SWK Holdings Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About SWK Holdings Corporation

SWK Holdings Corporation Announces Financial Results for Fourth Quarter 2023
SWK Holdings Corporation Announces Financial Results for Third Quarter 2023
SWK Holdings Corporation to Report Third Quarter 2023 Financial Results
SWK Holdings Corporation Announces B. Riley Securities Exercises Option to Purchase Approximately $3 Million in Additional Unsecured Senior Notes
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
SWK Holdings Corporation Increases Revolving Credit Facility to $60 Million
SWK Holdings Corporation Announces Closing of Public Offering of Senior Unsecured Notes Due 2027
SWK Holdings Corporation Announces Pricing of Public Offering of Senior Unsecured Notes Due 2027

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.